+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biologics Market Global Report 2017

  • ID: 4334080
  • Report
  • July 2017
  • Region: Global
  • 250 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Abbvie
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • MORE
Biologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs.

The Biologics Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global satellite and telecommunications resellers sector.

Reasons to Purchase:
  • Outperform competitors using accurate up to date demand-side dynamics information
  • Identify growth segments for investment
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market
  • Create regional and country strategies on the basis of local data and analysis
  • Stay abreast of the latest customer and market research findings.
  • Benchmark performance against key competitors
  • Develop strategies based on likely future developments
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Gain a global perspective on the development of the market
  • Report will be updated with the latest data and delivered to you within 1-2 working days of order
Description:

Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this
  • The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceutical market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The biologics Indicators Comparison
  • The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy
Scope:

Markets Covered: Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines
Companies Mentioned: Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time Series: Five years historic and forecast
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Biologics Indicators Comparison
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • MORE
1. Biologics Market Characteristics

2. Biologics Market Size And Growth
2.1. Historic Market Growth
2.1.1. Drivers Of The Market
2.1.2. Restraints On The Market
2.2. Forecast Market Growth
2.2.1. Drivers Of The Market
2.2.2. Restraints On The Market

3. Pestle Analysis
3.1. Political
3.2. Economic
3.3. Social
3.4. Technological
3.5. Legal
3.6. Environmental

4. Biologics Market Customer Information

5. Biologics Market Segmentation
5.1. Global Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
5.2. Global Biologics Market, 2012 - 2020, Historic And Forecast, By Segment
5.3 Global Biologics Market Trends And Strategies
5.4 Global Biologics Market Compared With Similar Markets, 2016
5.5 Global Biologics Market Compared With Similar Markets, 2012 - 2020, Historic and Forecast
5.6 Biologics Market Compared With Similar Markets, 2016, By Region
5.7 Biologics Market Compared With Similar Markets, 2016, By Country
5.8 Therapeutic Proteins
5.8.1. Market Characteristics
5.8.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment
5.8.3. Market Trends And Strategies
5.9 Monoclonal Antibodies (MABS)
5.9.1. Market Characteristics
5.9.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment
5.9.3. Market Trends And Strategies
5.10 Vaccines
5.9.1. Market Characteristics
5.10.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment
5.10.3. Market Trends And Strategies

6. Biologics Market Regional And Country Analysis
6.1. Global Biologics Market, 2016, By Region
6.2. Global Biologics Market, 2012 - 2020, Historic And Forecast, By Region
6.3. Biologics Market, 2016, By Country
6.4. Biologics Market, 2012 - 2020, Historic And Forecast, By Country
6.5. Global Healthcare Market Segments, 2016, By Region
6.6. Global Pharmaceuticals Market Segments, 2016, By Region
6.7. Global Healthcare Market Segments, 2016, By Country
6.8. Global Pharmaceuticals Market Segments, 2016, By Country

7. Global Biologics Market Comparison With Macro Economic Factors
7.1. Biologics Market Size, Percentage Of GDP, Global
7.2. Per Capita Average Biologics Expenditure, Global

8. Biologics Market Comparison With Macro Economic Factors Across Countries
8.1. Biologics Market Size, Percentage Of GDP, By Country
8.2. Per Capita Average Biologics Expenditure, By Country

9. Biologics Market Comparison With Industry Metrics
9.1. Global Number Of Pharmacists, 2016, By Country
9.2. Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country
9.3. Global Number Of Pharma Enterprises, 2016, By Country
9.4. Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country
9.5. Global Number Of Employees In Pharmaceutical Industry, 2016, By Country
9.6. Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country
9.7. Global Average Spending On R&D/Product Development, 2016, By Country
9.8. Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country
9.9. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.10. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country
9.11. Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
9.12. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country
9.13. Global Number Of Pharmacies, 2016, By Country
9.14. Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country
9.15. Global New Drug Approvals, 2016, By Country
9.16. Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country
9.17. Prevalent Cases Of Thalassemia, 2014, By Country
9.18. Global Number Of General Practitioners 2016, By Country
9.19. Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country

10. Asia-Pacific Biologics Market
10.1.1. Asia-Pacific Biologics Market Overview
10.1.2. Asia-Pacific Biologics Historic Market, 2012 - 2016
10.1.3. Asia-Pacific Biologics Forecast Market, 2016 - 2020
10.1.4. Asia-Pacific Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
10.2. Asia-Pacific Biologics Market: Country Analysis
10.3. China Biologics Market
10.3.1. China Biologics Market Overview
  • Average Salaries Of Pharmacists
10.3.2. China Biologics Historic Market, 2012 - 2016
10.3.3. China Biologics Forecast Market, 2016 - 2020
10.3.4. China Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
10.3.5. China Biologics Percentage Of GDP, 2012 - 2020
10.3.6. China Per Capita Average Biologics Expenditure, 2012 - 2020
10.4. India Biologics Market
10.4.1. India Biologics Market Overview
  • Average Salaries Of Pharmacists
10.4.2. India Biologics Historic Market, 2012 - 2016
10.4.3. India Biologics Forecast Market, 2016 - 2020
10.4.4. India Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
10.4.5. India Biologics Percentage Of GDP, 2012 - 2020
10.4.6. India Per Capita Average Biologics Expenditure, 2012 - 2020
10.5. Japan Biologics Market
10.5.1. Japan Biologics Market Overview
  • Average Salaries Of Pharmacists
10.5.2. Japan Biologics Historic Market, 2012 - 2016
10.5.3. Japan Biologics Forecast Market, 2016 - 2020
10.5.4. Japan Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
10.5.5. Japan Biologics Percentage Of GDP, 2012 - 2020
10.5.6. Japan Per Capita Average Biologics Expenditure, 2012 - 2020
10.5.7. Japan Biologics Market Comparison With Industry Metrics
10.5.7.1. Japan Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
10.5.7.2. Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
10.6. Australia Biologics Market
10.6.1. Australia Biologics Historic Market, 2012 - 2016
10.6.2. Australia Biologics Forecast Market, 2016 - 2020
10.6.3. Australia Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
10.6.4. Australia Biologics Percentage Of GDP, 2012 - 2020
10.6.5. Australia Per Capita Average Biologics Expenditure, 2012 - 2020

11. Western Europe Biologics Market
11.1.1. Western Europe Biologics Market Overview
11.1.2. Western Europe Biologics Historic Market, 2012 - 2016
11.1.3. Western Europe Biologics Forecast Market, 2016 - 2020
11.1.4. Western Europe Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
11.2. Western Europe Biologics Market: Country Analysis
11.3. UK Biologics Market
11.3.1. UK Biologics Market Overview
  • Average Salaries Of Pharmacists
11.3.2. UK Biologics Historic Market, 2012 - 2016
11.3.3. UK Biologics Forecast Market, 2016 - 2020
11.3.4. UK Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
11.3.5. UK Biologics Percentage Of GDP, 2012 - 2020
11.3.6. UK Per Capita Average Biologics Expenditure, 2012 - 2020
11.3.7. UK Biologics Market Comparison With Industry Metrics
11.3.7.1 UK Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.3.7.2 UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.4. Germany Biologics Market
11.4.1. Germany Biologics Historic Market, 2012 - 2016
11.4.2. Germany Biologics Forecast Market, 2016 - 2020
11.4.3. Germany Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
11.4.4 Germany Biologics Percentage Of GDP, 2012 - 2020
11.4.5 Germany Per Capita Average Biologics Expenditure, 2012 - 2020
11.4.6 Germany Biologics Market Comparison With Industry Metrics
11.4.7.1 Germany Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.4.7.2 Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.5 France Biologics Market
11.5.1 France Biologics Historic Market, 2012 - 2016
11.5.2 France Biologics Forecast Market, 2016 - 2020
11.5.3 France Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
11.5.4 France Biologics Percentage Of GDP, 2012 - 2020
11.5.5 France Per Capita Average Biologics Expenditure, 2012 - 2020
11.5.6 France Biologics Market Comparison With Industry Metrics
11.5.6.1 France Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.5.6.2 France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.6. Italy Biologics Market
11.6.1. Italy Biologics Historic Market, 2012 - 2016
11.6.2. Italy Biologics Forecast Market, 2016 - 2020
11.6.3. Italy Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
11.6.4. Italy Biologics Percentage Of GDP, 2012 - 2020
11.6.5. Italy Per Capita Average Biologics Expenditure, 2012 - 2020
11.6.6. Italy Biologics Market Comparison With Industry Metrics
11.6.6.1 Italy Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.6.6.2 Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.7. Spain Biologics Market
11.7.1. Spain Biologics Historic Market, 2012 - 2016
11.7.2. Spain Biologics Forecast Market, 2016 - 2020
11.7.3. Spain Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
11.7.4. Spain Biologics Percentage Of GDP, 2012 - 2020
11.7.5. Spain Per Capita Average Biologics Expenditure, 2012 - 2020
11.7.6. Spain Biologics Market Comparison With Industry Metrics
11.7.6.1 Spain Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
11.7.6.2 Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016

12. Eastern Europe Biologics Market
12.1.1. Eastern Europe Biologics Market Overview
12.1.2. Eastern Europe Biologics Historic Market, 2012 - 2016
12.1.3. Eastern Europe Biologics Forecast Market, 2016 - 2020
12.1.4 Eastern Europe Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
12.2. Eastern Europe Biologics Market: Country Analysis
12.3. Russia Biologics Market
12.3.1. Russia Biologics Historic Market, 2012 - 2016
12.3.2. Russia Biologics Forecast Market, 2016 - 2020
12.3.3. Russia Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
12.3.4. Russia Biologics Percentage Of GDP, 2012 - 2020
12.3.5. Russia Per Capita Average Biologics Expenditure, 2012 - 2020

13. North America Biologics Market
13.1.1. North America Biologics Market Overview
13.1.2. North America Biologics Historic Market, 2012 - 2016
13.1.3. North America Biologics Forecast Market, 2016 - 2020
13.1.4. North America Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
13.2. North America Biologics Market: Country Analysis
13.3. USA Biologics Market
13.3.1. USA Biologics Historic Market, 2012 - 2016
13.3.2. USA Biologics Forecast Market, 2016 - 2020
13.3.3 USA Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
13.3.4. USA Biologics Percentage Of GDP, 2012 - 2020
13.3.5. USA Per Capita Average Biologics Expenditure, 2012 - 2020
13.3.6. USA Biologics Market Comparison With Industry Metrics
13.3.6.1 USA Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016
13.3.6.2 USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012 - 2016

14. South America Biologics Market
14.1.1. South America Biologics Market Overview
14.1.2. South America Biologics Historic Market, 2012 - 2016
14.1.3. South America Biologics Forecast Market, 2016 - 2020
14.1.4. South America Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
14.2. South America Biologics Market: Country Analysis
14.3. Brazil Biologics Market
14.3.1. Brazil Biologics Historic Market, 2012 - 2016
14.3.2. Brazil Biologics Forecast Market, 2016 - 2020
14.3.3. Brazil Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
14.3.4. Brazil Biologics Percentage Of GDP, 2012 - 2020
14.3.5. Brazil Per Capita Average Biologics Expenditure, 2012 - 2020

15. Middle East Biologics Market
15.1.1. Middle East Biologics Market Overview
15.1.2. Middle East Biologics Historic Market, 2012 - 2016
15.1.3. Middle East Biologics Forecast Market, 2016 - 2020
15.1.4. Middle East Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
16.1.1. Africa Biologics Market Overview
16.1.2. Africa Biologics Historic Market, 2012 - 2016
16.1.3. Africa Biologics Forecast Market, 2016 - 2020
16.1.4. Africa Biologics Market, 2016, By Segment
  • Therapeutic Proteins
  • Monoclonal Antibodies (MABS)
  • Vaccines
17. Biologics Market Competitive Landscape
17.1. Company Profiles
17.2. Johnson & Johnson
17.2.1. Overview
17.2.2. Products And Services
17.2.3. Strategy
17.2.4. Financial Performance
17.3. Pfizer Inc.
17.3.1. Overview
17.3.2. Products And Services
17.3.3. Strategy
17.3.4. Financial Performance
17.4. Novartis Ag
17.4.1. Overview
17.4.2. Products And Services
17.4.3. Strategy
17.4.4. Financial Performance
17.5. Abbvie
17.5.1. Overview
17.5.2. Products And Services
17.5.3. Strategy
17.5.4. Financial Performance
17.6. Sanofi
17.6.1. Overview
17.6.2. Products And Services
17.6.3. Strategy
17.6.4. Financial Performance

18. Key Mergers And Acquisitions In The Biologics Market

19. Market Background: Pharmaceuticals Market
19.1.1. Pharmaceutical Market Characteristics
19.1.2. Pharmaceutical Market Historic Growth
19.1.2.1. Drivers Of The Market
19.1.2.2. Restraints Of The Market
19.1.3. Pharmaceutical Market Forecast Growth
19.1.3.1. Drivers Of The Market
19.1.3.2. Restraints Of The Market
19.1.4. Pharmaceutical Trends And Strategies
19.2. Pharmaceutical Market Regional And Country Analysis
19.2.1. Global Pharmaceutical Market, 2016, By Region
19.2.2. Global Pharmaceutical Market, 2012 - 2020, Historic And Forecast, By Region
19.2.3. Pharmaceutical Market, 2016, By Country
19.2.4. Pharmaceutical Market, 2012 - 2020, Historic And Forecast, By Country
19.2.5. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment
19.2.6. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceuticals Market Comparison With Macro Economic Factors
19.3.1. Pharmaceutical Market Size, Percentage Of GDP, Global
19.3.2. Per Capita Average Pharmaceutical Expenditure, Global
19.4. Pharmaceutical Market Comparison With Macro Economic Factors Across Countries
19.4.1. Pharmaceutical Market Size, Percentage Of GDP, By Country
19.4.2. Per Capita Average Pharmaceutical Expenditure, By Country
19.5. Key Mergers And Acquisitions In The Pharmaceutical Market

20. Pharmaceuticals Industry Financial Margins

21. Appendix
21.1. NAICS Definitions Of Industry Covered In This Report
21.2. Abbreviations
21.3. Currencies
21.4. Research Inquiries
21.5. About Us
21.6. Copyright And Disclaimer
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbvie
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • MORE
Biologics market covers biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnology methods and other cutting-edge technologies.

The global biologics market was estimated to be around $210 billion as of 2016. It made up around 20% of the overall pharmaceuticals market in 2016. The biologics was the second largest market, following the pharmaceutical drugs market in the global pharmaceutical market in 2016.

Treatment of Complex Diseases

Biologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan).
Note: Product cover images may vary from those shown
5 of 5
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Abbvie
  • Sanofi
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll